Hvivo以1 000万欧元购买德国公司的研究单位,目的是到2028年达到1亿英镑的收入。 Hvivo buys German firm's research units for €10 million, aiming to hit £100 million revenue by 2028.

临床试验公司Hvivo从德国CRS公司购买了两个研究单位,耗资1 000万欧元,扩大了欧洲的存在,在曼海姆和基尔增加了120张床位。 Clinical trials company Hvivo has acquired two research units from German firm CRS for €10 million, expanding its European presence and adding 120 beds in Mannheim and Kiel. 预计这一举措将使Hvivo2025年的收入增加到7 300万英镑,并有助于到2028年达到1亿英镑的目标。 This move is expected to boost Hvivo's 2025 revenues to £73 million and help reach a £100 million target by 2028. 购置符合Hvivo加强其早期药物开发服务和业务交付的战略。 The acquisition aligns with Hvivo's strategy to enhance its early-stage drug development services and operational delivery.